Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. - Wikidata - wikimedia - TriplyDB

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.

http://www.wikidata.org/entity/Q37129225

about

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study.Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry.Mucosal Healing in Ulcerative Colitis: A Comprehensive Review.Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

P2860

Q33819506-13900FDD-70A7-4DFA-B3C4-439D3F993F16 Q33819512-6BB3A55A-4ECD-4F40-8CA0-AFC645050E34 Q48357834-0DBA113B-FE2F-4C1D-97DC-E3A098A3CB2C Q53815697-284EAE8A-C9BF-45DA-96D5-52D1037E37EC Q57193103-798E82A2-0FA8-46B9-8FEF-08712A93E2E6

P2860

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.

http://www.wikidata.org/entity/Q37129225

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ulcerative Colitis Remission S ...... Outcomes: the MOMENTUM Trial.

@en

Ulcerative Colitis Remission S ...... Outcomes: the MOMENTUM Trial.

@nl

type

label

Ulcerative Colitis Remission S ...... Outcomes: the MOMENTUM Trial.

@en

Ulcerative Colitis Remission S ...... Outcomes: the MOMENTUM Trial.

@nl

prefLabel

Ulcerative Colitis Remission S ...... Outcomes: the MOMENTUM Trial.

@en

Ulcerative Colitis Remission S ...... Outcomes: the MOMENTUM Trial.

@nl

P1433

Q37129225-C485EB36-3E4B-4555-8F53-6742204188A9

P1476

Q37129225-07B0EB64-BFA9-44EA-B0BA-715F50FDCC00

P2093

Q37129225-06BA6B32-82E5-4A39-9684-ECB91B94D0BC

Q37129225-35B28C47-495F-410C-943C-B49CEC72DC9B

Q37129225-39EBAF12-8540-4F78-B076-E4730EF81E35

Q37129225-3C5292C7-80BE-4CB1-AD59-ED0287696F2D

Q37129225-3E171753-AEB9-459F-B9BD-FBC996CB97F6

Q37129225-3F5E0E90-8D73-4647-8699-D191AC230A2D

Q37129225-47B83140-2244-4F69-BF86-D4A13A0F055A

Q37129225-669ED756-F850-4736-983D-6F06FE99E23F

Q37129225-92F26348-A692-4F32-A25D-EF815AECE6C1

Q37129225-C7D591DB-94E3-48E0-B8B4-8B932194737E

P2860

Q37129225-1086F15F-5A5B-43F3-9C8F-04BDC50921E8

Q37129225-1663ED3E-A7D4-4B8D-BE6E-165B69FD6CF0

Q37129225-342B7D84-B1D3-42FF-8387-9992EE8F0E32

Q37129225-72A274F4-CE03-4D0A-9DEA-48CC22369882

Q37129225-9016B745-1EE3-466A-9A0D-FECF84013DC4

Q37129225-9B50ABB9-5A2F-4A08-90C6-FFFAD6A29947

Q37129225-ABCEBD41-B2F1-4BD3-A4B4-35BBDA088F66

Q37129225-AC1438F3-3161-45EC-82AE-B0265DB85ED2

Q37129225-CB23DA0D-5218-473B-A8A4-C52F8E99BE60

Q37129225-CCE9BA6B-FF84-40F3-B291-5570862EAAC4

P304

Q37129225-34F220F4-74B4-4691-82D8-6132A29E1579

P31

Q37129225-FF598BE2-BD4D-40A5-9A03-CBEAAE079E0C

P356

Q37129225-19E0875A-ACE5-455D-B7BE-7ADCEAE05DCD

P433

Q37129225-F97A09DB-47FC-4CF7-AF24-4A7104325692

P478

Q37129225-18AF4D03-0C5F-4240-A9FA-BCBEF6E0C944

P577

Q37129225-B3C5863F-128F-4E6D-A0B4-E80FBD80135B

P5875

Q37129225-B0618B33-810D-490B-949C-67E805413098

P698

Q37129225-69E2792B-456C-4DB1-95B3-CE57392E65D5

P932

Q37129225-65649275-F69E-46AE-8F1B-31C7D74EAAB5

P356

P1433

Journal of Crohn's and Colitis

P1476

Ulcerative Colitis Remission S ...... Outcomes: the MOMENTUM Trial.

@en

P2093

Daniela Dobru

http://www.w3.org/2001/XMLSchema#string

David T Rubin

http://www.w3.org/2001/XMLSchema#string

Dory Solomon

http://www.w3.org/2001/XMLSchema#string

Elizabeth Magee

http://www.w3.org/2001/XMLSchema#string

Geert D'Haens

http://www.w3.org/2001/XMLSchema#string

Juan Márquez

http://www.w3.org/2001/XMLSchema#string

Libor Gabalec

http://www.w3.org/2001/XMLSchema#string

Marc Bradette

http://www.w3.org/2001/XMLSchema#string

Susi Inglis

http://www.w3.org/2001/XMLSchema#string

Ulcerative Colitis Remission Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology and natural history of inflammatory bowel diseases

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

European evidence-based Consensus on the management of ulcerative colitis: Current management.

Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis

Systematic review: adherence issues in the treatment of ulcerative colitis.

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.

Quality of life of patients with ulcerative colitis: past, present, and future.

Ulcerative colitis: prevention of relapse.

Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose.

Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.

P304

925-933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ECCO-JCC/JJW049

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

295832681

http://www.w3.org/2001/XMLSchema#string

P698

26908939

http://www.w3.org/2001/XMLSchema#string

P932

4962361

http://www.w3.org/2001/XMLSchema#string